193 related articles for article (PubMed ID: 32713806)
1. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
[TBL] [Abstract][Full Text] [Related]
3. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
[TBL] [Abstract][Full Text] [Related]
5. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
Zettner EM; Gleser MA
Otolaryngol Head Neck Surg; 2018 Nov; 159(5):887-894. PubMed ID: 29914288
[TBL] [Abstract][Full Text] [Related]
6. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.
Gleser MA; Zettner EM
Int J Audiol; 2018 Dec; 57(12):917-924. PubMed ID: 30382794
[TBL] [Abstract][Full Text] [Related]
7. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
8. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
[TBL] [Abstract][Full Text] [Related]
9. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.
Garinis AC; Keefe DH; Hunter LL; Fitzpatrick DF; Putterman DB; McMillan GP; Gold JA; Feeney MP
Ear Hear; 2018; 39(1):69-84. PubMed ID: 28708814
[TBL] [Abstract][Full Text] [Related]
10. The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.
Garinis AC; Cross CP; Srikanth P; Carroll K; Feeney MP; Keefe DH; Hunter LL; Putterman DB; Cohen DM; Gold JA; Steyger PS
J Cyst Fibros; 2017 May; 16(3):401-409. PubMed ID: 28238634
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
[TBL] [Abstract][Full Text] [Related]
12. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis.
Elson EC; Meier E; Oermann CM
J Cyst Fibros; 2021 Mar; 20(2):284-287. PubMed ID: 32811788
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
14. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
15. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
McRorie TI; Bosso J; Randolph L
Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
[TBL] [Abstract][Full Text] [Related]
16. Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.
Ogier JM; Lockhart PJ; Burt RA
Hear Res; 2020 Feb; 386():107870. PubMed ID: 31864009
[TBL] [Abstract][Full Text] [Related]
17. Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis.
Garinis AC; Poling GL; Rubenstein RC; Konrad-Martin D; Hullar TE; Baguley DM; Burrows HL; Chisholm JA; Custer A; Hawe LD; Hunter LL; Marras TK; Ortiz CE; Petersen L; Steyger PS; Winthrop K; Zettner EM; Clark K; Hungerford M; Vachhani JJ; Brewer CC
Am J Audiol; 2021 Oct; 30(3S):800-809. PubMed ID: 34549989
[TBL] [Abstract][Full Text] [Related]
18. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
19. Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review.
Caumo DTM; Geyer LB; Teixeira AR; Barreto SSM
Braz J Otorhinolaryngol; 2017; 83(4):464-474. PubMed ID: 27894912
[TBL] [Abstract][Full Text] [Related]
20. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
Scheenstra RJ; Heijerman HG; Zuur CL; Touw DJ; Rijntjes E
Acta Otolaryngol; 2010 Feb; 130(2):253-8. PubMed ID: 19479457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
